Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03591731
Title Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Intergroupe Francophone de Cancerologie Thoracique
Indications

lung large cell carcinoma

neuroendocrine carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST